Cited by 472Antiplatelet Therapy and Cardiovascular DiseasesPharmacogenetics and Drug MetabolismCoronary Interventions and Diagnostics

The DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.

CYP2C19 Genotype, Clopidogrel Metabolism, Platelet Function, and Cardiovascular Events: A Systematic Review and Meta-analysis

Holmes, Michael V., Perel, Pablo, Shah, Tina, Hingorani, Aroon D., Casas, Juan P.·2011·JAMA

DOI 10.1001/jama.2011.1880

Open this paper in CoChat — free account

Abstract

CONTEXT: The US Food and Drug Administration recently recommended that CYP2C19 genotyping be considered prior to prescribing clopidogrel, but the American Heart Association and American College of Cardiologists have argued evidence is insufficient to support CYP2C19 genotype testing. OBJECTIVE: To appraise evidence on the association of CYP2C19 genotype and clopidogrel response through systematic review and meta-analysis. DATA SOURCES: PubMed and EMBASE from their inception to October 2011. STUDY SELECTION: Studies that reported clopidogrel metabolism, platelet reactivity or clinically relevant outcomes (cardiovascular disease [CVD] events and bleeding), and information on CYP2C19 genotype were included. DATA EXTRACTION: We extracted information on study design, genotyping, and disease outcomes and investigated sources of bias. RESULTS: We retrieved 32 studies of 42,016 patients reporting 3545 CVD events, 579 stent thromboses, and 1413 bleeding events. Six studies were randomized trials ("effect-modification" design) and the remaining 26 reported individuals exposed to clopidogrel ("treatment-only" design). In treatment-only analysis, individuals with 1 or more CYP2C19 alleles associated with lower enzyme activity had lower levels of active clopidogrel metabolites, less platelet inhibition, lower risk of bleeding (relative risk [RR], 0.84; 95% CI, 0.75-0.94; absolute risk reduction of 5-8 events per 1000 individuals), and higher risk of CVD events (RR, 1.18; 95% CI, 1.09-1.28; absolute risk increase of 8-12 events per 1000 individuals). However, there was evidence of small-study bias (Harbord test P = .001). When analyses were restricted to studies with 200 or more events, the point estimate was attenuated (RR, 0.97; 95% CI, 0.86-1.09). In effect-modification studies, CYP2C19 genotype was not associated with modification of the effect of clopidogrel on CVD end points or bleeding (P > .05 for interaction for both). Other limitations included selective outcome reporting and potential for genotype misclassification due to problems with the * allele nomenclature for cytochrome enzymes. CONCLUSION: Although there was an association between the CYP2C19 genotype and clopidogrel responsiveness, overall there was no significant association of genotype with cardiovascular events.

Integrity signals

Registry

Crossref · 10.1001/jama.2011.1880

Cites

71 of 71 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., & Altman, D. G. (2009) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2009.06.005 · Cited by 19,575
Prasugrel versus clopidogrel in patients with acute coronary syndromes
Wiviott, S. D., Braunwald, E., McCabe, C. H., Montalescot, G., Ruzyllo, W., Gottlieb, S., Neumann, F.-J., Ardissino, D., De Servi, S., Murphy, S. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706482 · Cited by 6,790
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation
(2001) · New England Journal of Medicine · doi:10.1056/nejmoa010746 · Cited by 6,470
Interaction revisited: the difference between two estimates.
Altman, D. G., & Bland, J. M. (2003) · BMJ · doi:10.1136/bmj.326.7382.219 · Cited by 3,203
Interpretation of random effects meta-analyses
Riley, R. D., Higgins, J. P. T., & Deeks, J. J. (2011) · BMJ · doi:10.1136/bmj.d549 · Cited by 2,884
Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic Events
Bhatt, D. L., Fox, K. A. A., Hacke, W., Berger, P. B., Black, H. R., Boden, W. E., Cacoub, P., Cohen, E. A., Creager, M. A., Easton, J. D., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060989 · Cited by 2,819
Cytochrome P-450 Polymorphisms and Response to Clopidogrel
Mega, J. L., Close, S. L., Wiviott, S. D., Shen, L., Hockett, R. D., Brandt, J. T., Walker, J. R., Antman, E. M., Macias, W. L., D, E. B. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0809171 · Cited by 2,496
Effect of clopidogrel added to aspirin in patients with atrial fibrillation
The ACTIVE Investigators (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0901301 · Cited by 2,102

Show all 70 references

Sorted by citations

Items 401–472 of 472

Genetics of Clopidogrel Poor Response
Fontana, P., & Reny, J. (2014) · doi:10.1002/9781118493984.ch35
A case of recurrent subacute stent thrombosis after acute coronary syndrome which required percutaneous cardiopulmonary support twice due to refractory ventricular arrhythmias
Oshima, T., Yajima, J., Oikawa, Y., Matsuno, S., Kano, H., Fukamachi, D., Murata, N., & Aizawa, T. (2015) · Journal of the Japanese Coronary Association · doi:10.7793/jcoron.21.14-00004
Spielt der Genotyp klinisch doch keine Rolle?
Diener, H. (2012) · InFo Neurologie + Psychiatrie · doi:10.1007/s15005-012-0084-0
Abstract 11886: Chronic Kidney Disease Status Modifies the Association of CYP2C19 Polymorphism in Predicting Clinical Outcomes Following Coronary Stent Implantation
Tabata, N., Hokimoto, S., Akasaka, T., Arima, Y., Kaikita, K., Nakagawa, K., & Ogawa, H. (2014) · Circulation
Antiplatelet therapy in ACS and A ‐ F ibAdvances in Cardiology, vol. 47, Antiplatelet therapy in ACS and A‐Fib. Editor(s) edited by V.L.Serebruany and D.Atar. Published by Karger AG, Basel. 2012. 170 pp, price $167.00. ISBN 978‐3‐318‐02168‐4
Ferro, A. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12103
Almanac 2013: stable coronary artery disease
Islam, S., & Timmis, A. (2013) · Wiener klinische Wochenschrift · doi:10.1007/s00508-013-0473-5
Reply to the letter by Alexopoulos et al “Platelet reactivity in patients with chronic kidney disease receiving adjunctive cilostazol compared with a high-maintenance dose of clopidogrel: Results of the Effect of Platelet Inhibition According to Clopidogrel Dose in Patients with Chronic Kidney Disease (PIANO-2 CKD) randomized study”
Woo, J. S., & Kim, W. (2012) · American Heart Journal · doi:10.1016/j.ahj.2012.01.035
Platelet inhibition in acute coronary syndromes: A complex intervention that needs optimization
Aguíar, C. (2012) · Revista Portuguesa de Cardiologia (English Edition) · doi:10.1016/j.repce.2012.02.005
Challenges and Opportunities in Implementing Pharmacogenomics Testing in the Clinics
Wisler, J., Wisler, J. W., Bansal, S., & Marsh, C. B. (2012) · Personalized Medicine · doi:10.2217/pme.12.64
Front-loading with clopidogrel plus aspirin followed by dual antiplatelet therapy in the prevention of early stroke recurrence
Censori, B. (2014) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2014.923758
Recent drug news
Nolan, M. (2012) · European Journal of Hospital Pharmacy · doi:10.1136/ejhpharm-2012-000168
CYP2C19 polymorphisms in drug metabolism and response
Chang, M. (2014) · Figshare
Enfermedad coronaria estable
Islam, S., & Timmis, A. (2014) · Redalyc (Universidad Autónoma del Estado de México)
Almanac 2011: stable coronary artery disease. The national society journals present selected research that has driven recent advances in clinical cardiology
Henderson, R. A., & Timmis, A. (2011) · Revista Portuguesa de Cardiologia · doi:10.1016/j.repc.2011.09.012
Ocena warto ści prognostycznej wybranych parametrów klinicznych (Predict Score) oraz testu oporno ści pytek krwi na klopidogrel (Multiplate) w przewidywaniu zdarze ń niedokrwiennych u pacjentów po zabiegach przezskórnej interwencji wie ńcowej.
Komosa, A. (2013)
Routine genotyping of patients on clopidogrel: Why the resistance?
Karthikeyan, G. (2015) · Indian Heart Journal · doi:10.1016/j.ihj.2015.04.008
Genotype Testing for Clopidogrel Responsiveness May Not Predict Events
Herrmann, H. C. (2012) · Journal watch · doi:10.1056/jc201201040000002
Альманах-2013: стабільна ішемічна хвороба серця*
Islam, S., & Timmis, A. (2014) · Український кардіологічний журнал
Tamoxifen metabolites can target both aromatase and estrogen receptors
Liu, J. (2015) · IUScholarWorks (Indiana University) · doi:10.7912/c2/1899
La Pharmacogénomique, meilleur exemple de médecine personnalisée
Siest, G., & Visvikis‐Siest, S. (2016) · HEGEL - HEpato-GastroEntérologie Libérale · doi:10.3917/heg.061.0010
Interest of platelet inhibition monitoring in intracranial arterial stenosis before stenting
Gory, B., Mazighi, M., Detante, O., Nakiri, G. S., Saint‐Maurice, J., Boubagra, K., & Houdart, E. (2014) · Revue Neurologique · doi:10.1016/j.neurol.2013.09.011
Lessons Learned from Negative Clinical Trials Evaluating Antithrombotic Therapy for Ischemic Heart Disease
Kang, H., & Roe, M. T. (2014) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-013-9532-6
“Previous studies demonstrated an association between residual, high on-treatment platelet reactivity and ischemic risk among patients undergoing PCI, but the same relationship was not seen in TRILOGYACS [28, 29].”
Background
P2Y12 and P2Y12-related genetic analysis
Tomiyama, Y. (2012) · Japanese Journal of Thrombosis and Hemostasis · doi:10.2491/jjsth.23.450
The role of clopidogrel in the management of ischemic heart disease
Homan, D. J., & Price, M. J. (2013) · Current Opinion in Cardiology · doi:10.1097/hco.0b013e3283606957
ALMANAC: THE NATIONAL SOCIETY JOURNALS PRESENT SELECTED RESEARCH THAT HAS DRIVEN RECENT ADVANCES IN CLINICAL CARDIOLOGY. STABLE CORONARY ARTERY DISEASE
Islam, S. (2014)
[Omega-3--clopidogrel can help!].
Huczek, Z. (2012) · PubMed
Pharmacogenetic Testing-An Unfulfilled Promise.
Campos-Outcalt, D. E. (2015) · PubMed
pharmacokinetics of clopidogrel in healthy volunteers.
Funck‐Brentano, C., Szymezak, J., Steichen, O., Molimard, M., & Azizi, M. (2013)
Problems in Pharmacogenomics Testing
Greene, D. N., Vaughn, C. P., & Lyon, E. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-415783-5.00022-0
Essential Pharmacogenomic Biomarkers in Clinical Practice
Feng, X., & Xie, H.-G. (2016) · CRC Press eBooks · doi:10.1201/b19000-7
Antithrombotic Therapy for Treatment of Acute Ischemic Stroke
Adams, H. P., & Davis, P. H. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4160-5478-8.10050-8
Impacto de la evaluación de la reactividad plaquetar y de la presencia de polimorfismos del citocromo P450, 2C19 y paraoxonasa 1 en pacientes remitidos para intervencionismo percutáneo sometidos doble antiagregación
Vivar, P. C. (2016) · Tesis Doctorals en Xarxa (Consorci de Serveis Universitaris de Catalunya)
Recent advances in ischemic stroke management
Yoon, C. W., & Rha, J. (2016) · Journal of Korean Medical Association · doi:10.5124/jkma.2016.59.10.775
“그러나 이전에 발표된 메타분석 결과에서는 CYP2C19의 유전적 다형성에 따라 클로피도그렐의 혈소판 억제기능에 차이는 있었으나, 이러한 차이가 임상적인 심혈 관질환 발생의 차이로 연결되지는 않았다[20].”
The Role of Genetics in Acute Coronary Syndrome
Chandrasekhar, J., & Mehran, R. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803312-8.00003-3
Thrombotics and Antithrombotics
Slattery, D. E., & Pollack, C. V. (2012)
CYP2C19 Polymorphism and Clinical Outcomes among Patients of Different Races Treated with Clopidogrel: A Systematic Review and
Niu, X., Mao, L., Huang, Y. Y., Baral, S., Gao, Y. J., Xia, Y., Wang, M., Miao, X., & Hu, B. (2015)
Pharmacogenomics and Cardiovascular Disease
Dornblaser, E. K., Worby, C. P., & Brazeau, D. A. (2017) · Advances in medical diagnosis, treatment, and care (AMDTC) book series · doi:10.4018/978-1-5225-2092-4.ch009
Pharmacokinetics of montelukast and zafirlukast as affected by CYP inhibitors
Karonen, T. (2012) · Työväentutkimus Vuosikirja
Современные аспекты фармакогенетики клопидогрела и его клиническое значение
Golukhova, E. Z., Grigorian, M. V., & Николаевна, Р. М. (2014) · Креативная кардиология
Genomics-Guided Antithrombotic Therapy for Acute Coronary Syndromes
Ruff, C. T., & Sabatine, M. S. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-801812-5.00003-2
CYP2C19 PHARMACOGENETIC TESTING FOR PERSONALIZATION OF ANTIPLATELET THERAPY IN PATIENTS WITH ACUTE CORONARY SYNDROME IN ROUTINE CLINICAL PRACTICE
Akhmetova, I., Борисовна, К. Е., Sychev, D. A., Parshina, O. V., & Yashina, L. P. (2017) · Rational Pharmacotherapy in Cardiology · doi:10.20996/1819-6446-2017-13-6-771-775
Gene Therapy and Genomic Application in Heart Disease
Zhu, F., & Huang, K. (2018) · Translational bioinformatics · doi:10.1007/978-981-13-1429-2_13
Clopidegrol Resistance in Patients Undergoing Percutaneous Coronary Intervention (PCI): our experiences at Apollo Hospitals Dhaka
Islam, A. W., Munwar, S., Hossain, A., Reza, A., Talukder, S., Ahmed, T., & Rahman, M. (2019) · Cardiovascular Journal · doi:10.3329/cardio.v12i1.43419
Pharmacogenomics in Perioperative Care
Koress, C. M., Novitch, M. B., Renschler, J. S., Kaye, A. D., & Urman, R. D. (2020) · Springer eBooks · doi:10.1007/978-3-030-33443-7_13
Platelet Reactivity Is Preferred Over Genotyping in Monitoring Efficacy of Antiplatelet Therapy
Breet, N. J., & ten Berg, J. M. (2014) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2014.01.153
“This is in line with a large meta-analysis on CYP2C19 genotyping and outcome in clopidogrel-treated patients, which demonstrated an association between CYP2C19 genotype and on-treatment platelet reactivity but lacked proof of a significant association of genotype with cardiovascular events (6).”
Result
Antithrombotic Therapy for Treatment of Acute Ischemic Stroke
Adams, H. P., & Davis, P. H. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-29544-4.00052-9
CYP2C19*2, CYP2C19*17 and ITGB3 (PlA1/A2) polymorphisms and resulting therapeutic alterations of clopidogrel and aspirin: A clinical screening among CVD patients who undergone PCIPreprint
Nova, T. T., Jahan, I., Momenuzzaman, N., Rabbi, S. N. I., Binder, T. M. C., Islam, M. S., Islam, M. R., Hasnat, A., & Nahar, Z. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.10.04.325258
“It has been demonstrated by several pharmacogenomic studies that CYP2C19 variant alleles affect the pharmacokinetics and pharmacodynamics of clopidogrel and influence the inter-individual heterogeneity in clopidogrel response [6-12].”
Background
Genetic Polymorphisms Impact Response to Clopidogrel in Feline Hypertrophic CardiomyopathyPreprint
Ueda, Y., Li, R. H. L., Nguyen, N. H., Ontiveros, E. S., Fousse, S. L., Oldach, M. S., Vernau, K. M., Court, M. H., & Stern, J. A. (2021) · Research Square · doi:10.21203/rs.3.rs-138797/v1
Acute coronary syndromes and percutaneous coronary intervention—current recommendations for dual antiplatelet therapy. Are guidelines reflecting the data?
Ranard, L. S., & Brener, S. J. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820536-5.00002-1
POLIMORFISME CYP2C19*2 TERHADAP AGREGASI PLATELET DAN KEJADIAN KARDIOVASKULAR PADA PASIEN PENYAKIT JANTUNG KORONER
Utami, P. R., Rochmawati, I. D., & Fandinata, S. S. (2021) · Jurnal Ilmiah Manuntung · doi:10.51352/jim.v7i1.405
Genetic and nongenetic factors in assessing the prognosis of patients after myocardial infarction with high medical adherence
Pereverzeva, K. G., Yаkushin, S. S., Galus, A. S., & Shanina, A. R. (2021) · CARDIOVASCULAR THERAPY AND PREVENTION · doi:10.15829/1728-8800-2021-2773
Applying Pharmacogenomics in Drug Therapy of Cardiovascular Disease
Zhu, Y., Takahashi, P. Y., Pereira, N. L., Matey, E. T., & Borah, B. J. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00215-2
“In a meta-analysis conducted by Holmes et al., 32 studies on CYP2C19 and patient outcomes were synthesized and 42,016 patients who underwent PCI, clopidogrel therapy and genetic testing were followed-up with a mean time of 24 months (Holmes et al., 2011).”
Clopidogrel in clinical practice for myocardial revascularisation: from the origins to the latest recommendations
Grazhdankin, I. O., Baystrukov, V. I., Kretov, E. I., & Chernyavskiy, A. М. (2022) · Patologiya krovoobrashcheniya i kardiokhirurgiya · doi:10.21688/1681-3472-2022-1-32-43
Pharmacogenomics and Cardiovascular Disease
Dornblaser, E. K., Worby, C. P., & Brazeau, D. A. (2018) · IGI Global eBooks · doi:10.4018/978-1-5225-7122-3.ch010
Clinical Pharmacogenomics
López-Correa, C., & Gelbert, L. M. (2012) · Springer eBooks · doi:10.1007/978-1-4614-4800-6_39
Pharmacogenetics
Jain, K. K. (2015) · Springer eBooks · doi:10.1007/978-1-4939-2553-7_4
Diagnostics and Prevention: Landscape for Technology Innovation in Precision Cardiovascular Medicine
Mauch, J., Thachil, V., & Tang, W. H. W. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-816861-5.00004-6
Almanac 2013: Stable coronary artery disease the national society journals present selected research that has driven recent advances in clinical cardiology
Timmis, A. (2014) · Srce i krvni sudovi · doi:10.5937/siks1404288t
Essential Pharmacogenomic Biomarkers in Clinical Practice
Liu, C., Chen, W., & Zhang, W. (2016) · CRC Press eBooks · doi:10.1201/b19000-4
Antiplatelet treatment in acute myocardial infarction
Bergmeijer, T. O. (2023) · Research Publications (Maastricht University) · doi:10.26481/dis.20230530tb
Cardiovascular pharmacogenomics – Molecular basis of protective and adverse drug response
du Toit, C., Kassi, M., & Padmanabhan, S. (2024) · Elsevier eBooks · doi:10.1016/b978-0-12-822951-4.00012-6
Pharmacogenomics – challenges and opportunities for precision medicine
Padmanabhan, S., Lip, S. Z. L., & Dominiczak, A. F. (2025) · Elsevier eBooks · doi:10.1016/b978-0-323-95311-5.00004-x
Pharmacogenomics
Noor, D. A. M., & Daud, N. A. A. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33947-9.00013-x
Drugs that affect blood coagulation, fibrinolysis, and hemostasis
Gonsalves, W. I., & Patnaik, M. M. (2014) · Side effects of drugs annual · doi:10.1016/b978-0-444-62635-6.00035-8
Additional file 1 of The efficacy of clopidogrel in preventing recurrent cardiovascular events among Arab population carrying different CYP2C19 mutations: systematic review and meta-analysis
Alkattan, A., Radwan, N. M., Mahmoud, N., Alfaleh, A., Alfaifi, A. H., & Alabdulkareem, K. I. (2022) · Figshare · doi:10.6084/m9.figshare.20056320
Guided or Unguided Antiplatelet Therapy: Clarifying the Ambiguity
Liang, H.-W., & Wang, T. (2025) · Journal of Asian Pacific Society of Cardiology · doi:10.15420/japsc.2025.16
Impact of CYP2C19 genotyping on clopidogrel therapy adjustments in patients with stroke or TIA
Keyany, A., Leenders, T., & Maat, B. (2026) · European Journal of Hospital Pharmacy · doi:10.1136/ejhpharm-2025-004727
Pharmacogenomics: Foundation, Clinical Applications and Emerging Role of Artificial Intelligence in Personalized Medicine
Uppal, K., Haq, S. I. U., Malik, S., & Ashraf, R. (2026) · Pan-African Journal of Health and Psychological Sciences · doi:10.64261/tssvyh57
CYP2C19 Polymorphism and Platelet Aggregation‐Associated Risks in Atrial Fibrillation Patients Undergoing PCI
Gjermeni, D., Szabó, S., Anfang, V., Vetter, H., Juelch, C., Alter, S., Li, T., Leggewie, S., Hesselbarth, D., Duerschmied, D., et al. (2026) · Clinical and Translational Science · doi:10.1111/cts.70598
Association Between Diabetes Mellitus and Cytochrome P450 Family 2 Subfamily C Member 19 (CYP2C19) Loss-of-Function Allele Carriage Among Patients Undergoing Coronary Artery Bypass Grafting: A Cross-Sectional Study
Shawkat, M. S. B.-T., Kabir, A. S. M. H., Ahmed, I., Reza, M. S., & Bulbul, M. R. H. (2026) · Cureus · doi:10.7759/cureus.111991
“Previous investigations have shown that patients with diabetes often exhibit higher residual platelet activity during clopidogrel treatment compared with nondiabetic individuals, suggesting that metabolic disturbances may further modify treatment response [11,12].”
Genetic polymorphism of CYP2C19 in recurrent ischemic stroke patients: prevalence and role in secondary prevention
Saadawy, S. F., Sarhan, N. T., & Eldaly, M. M. (2026) · The Egyptian Journal of Neurology Psychiatry and Neurosurgery · doi:10.1186/s41983-026-01209-x
Precision Cardiovascular Medicine: Integrating Pharmacogenomics, Biomarkers, Artificial Intelligence, and Real-World Evidence
Alshahrani, A. M., Selvaraj, L., Kandasamy, G., & Anandan, S. (2026) · Life · doi:10.3390/life16111771

Authors: Holmes, M. V., Perel, P., Shah, T., Hingorani, A. D., & Casas, J. P.
Affiliations: University College London (GB)
Northwestern University (US)
ORCID: Holmes, Michael V.
Perel, Pablo
Shah, Tina
Hingorani, Aroon D.
Casas, Juan P.
Venue: JAMA
Publisher: American Medical Association (AMA)
Published: 2011-12-28
Volume: 306
Issue: 24
Pages: 2704
ISSN: 0002-9955 (ISSN-L)
0098-7484
DOI: 10.1001/jama.2011.1880
OpenAlex: W2119186881
Cited by: 472
References: 70
Citations by year: 2026: 10 · 2025: 10 · 2024: 7 · 2023: 13 · 2022: 18 · 2021: 22 · 2020: 19 · 2019: 27 · 2018: 23 · 2017: 25 · 2016: 36 · 2015: 46 · 2014: 53 · 2013: 89 · 2012: 70
FWCI: 47.48
Type: journal article
Language: en
Open access: closed
Locations: JAMA (publishedVersion)
PubMed (publishedVersion)
Funders: National Institute for Health and Care Research (RP-PG-0407-10314)
British Heart Foundation (FS05/125)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Coronary Interventions and Diagnostics
Keywords: CYP2C19 genotype, clopidogrel, clopidogrel response, platelet function, platelet aggregation inhibition, cardiovascular events, bleeding risk, stent thrombosis, genotype testing, pharmacogenetics, small-study bias, effect modification, clopidogrel resistance, clopidogrel hypersensitivity, clopidogrel metabolite
MeSH terms: Clopidogrel, Aryl Hydrocarbon Hydroxylases, Cardiovascular Diseases, Genotype, Hemorrhage, Humans, Platelet Aggregation, Platelet Aggregation Inhibitors, Platelet Function Tests, Risk, Thrombosis, Ticlopidine, Angioplasty, Balloon, Coronary, Randomized Controlled Trials as Topic, Cytochrome P-450 CYP2C19

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

CYP2C19 Genotype, Clopidogrel Metabolism, Platelet Function, and Cardiovascular Events: A Systematic Review and Meta-analysis

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks